On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. When the comment window closes on June 29, the remaining legal pathway for bulk GLP-1s seals — and inspectors will work backward through the authorization logic behind every release, EAC determination, and CFU continuation decision in the prior twelve months.
Read intelligence →The Hidden Cost of GMP Decision Reconstruction
Every GMP organization can prove what it decided. Fewer can still explain why — and reconstructing that reasoning after the fact is a recurring, unbudgeted operating expense, not a documentation gap. This analysis traces the six-stage reconstruction cycle that repeats across deviations, CAPAs, batch releases, and change control, and what it costs to keep paying for the same reasoning twice.
What quality leaders should be watching
The 503B Regulatory Cliff: What an Inspector Will Reconstruct After June 29
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. When the comment window closes on June 29, the remaining legal pathway for bulk GLP-1s seals — and inspectors will work backward through the authorization logic behind every release, EAC determination, and CFU continuation decision in the prior twelve months.
Read the analysis →The Inspector Doesn't Ask If You Found the Root Cause. She Asks Who Authorized the Conclusion.
The investigation was complete. The root cause was documented. The CAPA was opened. When the inspector asked who authorized the root cause conclusion — the record that should have answered that question did not exist.
Read the analysis →The Decision Was Right. The Record Still Failed.
The inspector isn't reviewing your deviation. They're evaluating your judgment.
Read the analysis →The Reconstruction Tax: What It Actually Costs to Answer "Who Decided?"
Modeled hours spent reconstructing a single deviation decision after the fact — emails searched, meetings convened, and staff-hours burned — set against organizations that captured the rationale at the moment of judgment.
The Same Six Steps, Every Time
A GMP decision gets authorized. The QMS records the outcome. The reasoning behind it doesn't fully survive. Someone later asks why — an inspection, an audit, a repeat deviation, a leadership change — and the organization reconstructs a decision it already made once.
This is the structural model behind every case file in The Inspection Record's authorization library, starting with 21 CFR 211.192.
See the full framework →Deviation Root Cause Authorization Record
The governing artifact for defensible deviations disposition — built for the moment an investigator asks who decided, and why, before the record was closed.
Ten desks, one authorization standard
FDA Enforcement
Regulatory actions & inspection outcomes
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. When the comment window closes on June 29, the remaining legal pathway for bulk GLP-1s seals — and inspectors will work backward through the authorization logic behind every release, EAC determination, and CFU continuation decision in the prior twelve months.
CAPA
Corrective & preventive action
The corrective action was implemented. The effectiveness check was completed. The CAPA was closed. When the inspector asked who authorized the effectiveness determination — the record that should have answered that question did not exist.
Deviations
Investigation & root cause disposition
Batch Release
Disposition & release authorization
Root Cause
Causal analysis & conclusion authorization
OOS
Out-of-specification investigation
Change Control
Risk assessment & change authorization
Validation
Process & system qualification evidence
Data Integrity
Records, attribution & evidence
Authorization Records
Decision governance across the QMS